Showing results (31-40 of 92) with videos related to

Sort By:
Pageof 10
Frontiers in Endocrinology|July 6, 2023
<i>Post hoc</i> analysis of a randomized, double-blind, prospective trial evaluating a CXCR1/2 inhibitor in new-onset type 1 diabetes: endo-metabolic features at baseline identify a subgroup of respondersValeria Sordi, Paolo Monti, Vito Lampasona, et al.
Diabetes Care|September 18, 2013
Minimal functional β-cell mass in intraportal implants that reduces glycemic variability in type 1 diabetic recipientsPieter Gillard, Robert Hilbrands, Ursule Van de Velde, et al.
Transplantation|July 9, 2005
Alloreactivity against repeated HLA mismatches of sequential islet grafts transplanted in non-uremic type 1 diabetes patientsCorine A van Kampen, Pieter van de Linde, Gaby Duinkerken, et al.
Diabetes Care|July 1, 2011
Contribution of antibodies against IA-2β and zinc transporter 8 to classification of diabetes diagnosed under 40 years of ageIlse Vermeulen, Ilse Weets, Milca Asanghanwa, et al.
Diabetes Care|July 14, 2017
Twenty-Year Progression Rate to Clinical Onset According to Autoantibody Profile, Age, and <i>HLA-DQ</i> Genotype in a Registry-Based Group of Children and Adults With a First-Degree Relative With Type 1 DiabetesFrans K Gorus, Eric V Balti, Anissa Messaaoui, et al.
The Journal of Clinical Endocrinology and Metabolism|January 18, 2018
Effect of Continuous Glucose Monitoring on Glycemic Control, Acute Admissions, and Quality of Life: A Real-World StudySara Charleer, Chantal Mathieu, Frank Nobels, et al.
Plos One|January 12, 2016
Serum Cytokines as Biomarkers in Islet Cell Transplantation for Type 1 DiabetesCornelis R van der Torren, Annemarie A Verrijn Stuart, DaHae Lee, et al.
The Journal of Clinical Endocrinology and Metabolism|March 28, 2015
Plasma GAD65, a Marker for Early β-Cell Loss After Intraportal Islet Cell Transplantation in Diabetic PatientsZhidong Ling, Pieter De Pauw, Daniel Jacobs-Tulleneers-Thevissen, et al.
Diabetes Research and Clinical Practice|October 26, 2023
Baseline plasma proinsulin response to glucose for predicting therapeutic response to otelixizumab in recent-onset type 1 diabetesAster K Desouter, Bart Keymeulen, Simke Demeester, et al.
Stem Cells Translational Medicine|August 6, 2019
Cell Mass Increase Associated with Formation of Glucose-Controlling β-Cell Mass in Device-Encapsulated Implants of hiPS-Derived Pancreatic EndodermThomas Robert, Ines De Mesmaeker, Freya O Van Hulle, et al.
Pageof 10